In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Medical Services Patients & Visitors Health Library For Medical Professionals Quality About Us PhysicianLink
Text Size:  -   +  |  Print Page  |  Email Page

Neurology & Stroke Research



Research is one of the components that make us unique at Baptist Health Lexington.  Our highly trained staff is dedicated to providing the latest innovations and newest therapies in a community-based setting.  We are working to improve the lives of our stroke and neurological patients.

Below is a listing of current stroke/neurology clinical trials:

 

 

IRB# 1203 —Stratis Registry:

Title: The systematic Evaluation of Patients Treated with Neurothrombectomy Devices for Acute Ischemic Stroke Registry.

Sponsored by:  Covidien

Status:Enrolling

 

Purpose: a registry to assess clinical outcomes associated with the use of Covidien market released neurothrombectomy devices intended to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion.

 

Main Eligibility:  Patients diagnosed with an acute ischemic stroke due to large intracranial vessel occlusion and treated with Coviden market-released neurothrombectomy devises

 

 Up to 1000 patients will be enrolled at 60 US sites

 

For additional information, please contact Linda Breathitt RN or Sara Renfrow at 859.260.6344.

 

 

IRB# 555— CREST

Title: Carotid Revascularization by Endarterectomy vs. Stenting Trial.

Sponsored by: National Institute of Neurological Disorders and Stroke (NINDS) and the University of Medicine and Dentistry of New Jersey (UMDNJ)

Status: Closed to enrollment, enrolled patients in 10 year follow-u

 

Purpose: To contrast the relative efficacy of Carotid Artery Stenting (CAS) versus Carotid Endarterectomy (CEA) in preventing stroke, myocardial infarction, and death during a 30-day peri-procedural period and stroke ipsilateral to the study artery over the follow-up period (up to 10 years) in patients with symptomatic and asymptomatic extracranial carotid stenosis

 

For additional information, please contact Linda Breathitt RN or Sara Renfrow at 859.260.6344.

 

 

IRB# 1080—SWIFT:

 

Title: Solitaire™ With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial

Sponsor: Covidien

Status: Enrolling

 

Purpose:  Randomized study to determine if subjects experiencing an acute ischemic stroke due to a large vessel occlusion, treated with combined IV TPA and Solitaire FR (mechanical thrombectomy intervention) within 6 hours of symptom onset have less stroke related disability than those subjects treated with TPA alone.

 

Patients will be followed for 90 days.

 

Eligibility:Patients who have suffered a large stroke during previous 6 hours due to a blood clot blocking the flow of the blood to the brain.

 

For additional information, please contact Linda Breathitt RN or Sara Renfrow at 859.260.6344.

 

 

IRB# 1131 Weave:

Title: Wingspan® Stent System Post Market Surveillance Study

Sponsor:  Stryker Neurovascular

Status:  Enrolling

 

Purpose:  To evaluate patients treated with the Wingspan® stent system according to the new FDA approved indications for use.

 

The research study is a post market surveillance study of the Wingspan® Stent System with Gateway® Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, also known as the WEAVE™ Trial.  The Wingspan Stent System with Gateway PTA Balloon Catheter is a Humanitarian Use Device (HUD).  A HUD is a device used to diagnose or treat a disease or condition that affects fewer than 4,000 individuals in the United States (U.S.) per year and for which no comparable device is available.  The U.S. Food and Drug Administration (FDA) approves the use of HUD devices to give patients a treatment option that may potentially benefit them.  HUD devices have not been proven to provide benefit.

 

Main Eligibility: Patients with symptomatic intracranial atherosclerotic disease refractory to medical management.

 

For additional information, please contact Linda Breathitt RN or Sara Renfrow at 859.260.6344.

 

 

IRB # 1114—Transform:

Title: Transform™ Occlusion Balloon Catheter Registry

Sponsor: Stryker Neurovascular

Status: Enrolling

 

Purpose:  a registry to collect data on the use of the TransForm Occlusion Balloon Catheter (OBC) when it is used during procedures on the vessels in the brain (neurovascular procedure). The TransForm OBC is cleared by the FDA for use in brain vessels (neurovasculature) to temporarily stop or control blood flow and for balloon assisted embolization (coiling) of aneurysms. Your doctor can use the TransForm OBC outside of this registry. This registry will look at how the TransForm OBC is used and performs.

 

For additional information, please contact Linda Breathitt RN or Sara Renfrow at 859.260.6344.